Discover investment opportunities in SMALLCAPSTOCKS2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in SMALLCAPSTOCKS2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in SMALLCAPSTOCKS2024 using our Smart AI Filter.
9 stocks found for "SMALLCAPSTOCKS2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.81 | ±51.8% | 40.9 | 0.00% | |||
0.65 | ±100.0% | 14.7 | 0.00% | |||
1.48 | ±100.0% | 13.6 | 0.00% | |||
0.56 | ±100.0% | -6.0 | 0.00% | |||
0.52 | ±100.0% | -15.4 | 0.00% | |||
0.98 | ±39.2% | 6.6 | 10.79% | |||
1.52 | ±77.6% | -61.0 | 0.00% | |||
0.95 | ±80.3% | 15.4 | 7.49% | |||
1.21 | ±100.0% | 281.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreThe mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read moreQ: What potential does PCT have for growth within the plastic recycling industry?
A: PureCycle Technologies (PCT) focuses on recycling polypropylene to produce virgin-like recycled plastic. With increasing demand for sustainable materials, PCT's unique recycling process and potential scalability present significant growth opportunities. However, their success depends on their ability to ramp up production effectively and manage operational expenses.
Q: Is ESPR considered a high-risk investment compared to other small-cap stocks?
A: Esperion Therapeutics (ESPR) is considered high-risk due to its focus on a narrow portfolio of cholesterol-lowering treatments. As a pharmaceutical company, success hinges on clinical trial outcomes, regulatory approvals, and market acceptance, making it inherently volatile compared to diversified, non-biotech small caps.
Q: How does AVXL's focus on neurodegenerative diseases impact its stock performance?
A: Anavex Life Sciences (AVXL) researches treatments for neurodegenerative and rare diseases, creating potential for significant breakthroughs. Positive clinical trial results can lead to substantial stock appreciation. However, research outcomes are unpredictable, and unsuccessful trials may negatively impact performance.
Q: What factors make CRUS attractive in the tech sector?
A: Cirrus Logic (CRUS) specializes in audio and voice IC products, supplying major tech companies like Apple. Its strength lies in innovation and integration into popular consumer electronics, offering potential growth. However, reliance on a few large clients could pose risks if technological demands shift.
Q: Are dividend yields from INSG reliable for long-term income investors?
A: Inseego Corp. (INSG) currently does not pay dividends. Investors seeking long-term income should consider other factors like their focus on mobile and IoT solutions, which may contribute to capital gains, but not reliable dividend income.
Q: Does BLDP pose any sector-specific risks within the clean energy market?
A: Ballard Power Systems (BLDP), as a hydrogen fuel cell technology company, faces risks such as rapidly changing regulatory environments, technological advancements from competitors, and the high capital cost of scaling operations. These factors can affect profitability in the clean energy sector.